Company

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

CompanyDeals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Henlius Biotech Secures Exclusive China Rights to CTFH's Third-Generation EGFR TKI FHND9041 for NSCLC
CompanyDeals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

CompanyDrug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

CompanyDrug

Leads Biolabs’ Opamtistomig Becomes World’s First 4-1BB Bispecific Antibody to Enter Pivotal Phase III for EP-NEC

CompanyDrug

CSPC Pharmaceutical Receives NMPA Clinical Trial Approval for SYH2095, World’s First KAT6 Inhibitor

CompanyDeals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Boehringer Ingelheim's JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis
CompanyDrug

Boehringer Ingelheim’s JASCAYD (Nerandomilast) Approved in Japan for IPF and Progressive Pulmonary Fibrosis

Bayer's HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment
CompanyDrug

Bayer’s HYRNUO Receives FDA Priority Review for First-Line HER2-Mutated NSCLC Treatment

CompanyDeals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

CompanyDrug

Sanegene Bio’s C3-Targeted siRNA SGB-9768 Expands to Hematological Disorders Following NMPA Clinical Trial Approval

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town
CompanyDeals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town